Robert L. Fine, MD, from Columbia University, comments on the utility of CAPTEM in chemotherapy-resistant neuroendocrine tumors.
Robert L. Fine, MD
Advertisement
Articles by Robert L. Fine, MD
Robert L. Fine, MD, from Columbia University, discusses reducing the risk of relapse in patients with pancreatic cancer.
Advertisement
Latest Updated Articles
The Utility of CAPTEM in Chemo-Resistant Neuroendocrine TumorsPublished: April 24th 2014 | Updated:
Reducing the Risk of Relapse in Patients With Pancreatic CancerPublished: February 24th 2014 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
4
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
5
